Ieq Capital LLC Acquires Shares of 128,792 Sana Biotechnology, Inc. $SANA

Ieq Capital LLC bought a new stake in Sana Biotechnology, Inc. (NASDAQ:SANA) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 128,792 shares of the company’s stock, valued at approximately $449,000.

Other hedge funds have also recently bought and sold shares of the company. Xponance LLC increased its position in shares of Sana Biotechnology by 25.6% during the 4th quarter. Xponance LLC now owns 13,068 shares of the company’s stock valued at $53,000 after purchasing an additional 2,662 shares during the period. Creative Planning grew its holdings in shares of Sana Biotechnology by 5.3% during the third quarter. Creative Planning now owns 54,177 shares of the company’s stock valued at $192,000 after buying an additional 2,719 shares in the last quarter. Rockefeller Capital Management L.P. increased its holdings in shares of Sana Biotechnology by 74.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after purchasing an additional 4,088 shares during the period. Polymer Capital Management US LLC lifted its position in Sana Biotechnology by 32.5% in the 4th quarter. Polymer Capital Management US LLC now owns 18,285 shares of the company’s stock worth $74,000 after buying an additional 4,480 shares in the last quarter. Finally, Captrust Financial Advisors boosted its position in Sana Biotechnology by 43.8% during the second quarter. Captrust Financial Advisors now owns 15,793 shares of the company’s stock valued at $43,000 after purchasing an additional 4,807 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Stock Performance

Shares of SANA opened at $3.93 on Friday. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -5.17 and a beta of 2.16. Sana Biotechnology, Inc. has a 52 week low of $2.61 and a 52 week high of $6.55. The business’s fifty day moving average price is $3.57 and its two-hundred day moving average price is $3.42.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. As a group, research analysts forecast that Sana Biotechnology, Inc. will post -0.72 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Bank of America cut their target price on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Wall Street Zen lowered Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Weiss Ratings raised shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. TD Cowen raised shares of Sana Biotechnology to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Rodman & Renshaw started coverage on Sana Biotechnology in a research note on Monday, May 11th. They set a “buy” rating and a $16.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and an average target price of $9.33.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.